Literature DB >> 25580586

Isoliquiritigenin as a cause of DNA damage and inhibitor of ataxia-telangiectasia mutated expression leading to G2/M phase arrest and apoptosis in oral squamous cell carcinoma.

Shih-Min Hsia1, Cheng-Chia Yu2,3, Yin-Hua Shih2, Michael Yuanchien Chen4,5, Tong-Hong Wang6, Yu-Ting Huang2,7, Tzong-Ming Shieh7.   

Abstract

BACKGROUND: Isoliquiritigenin (ISL), a natural compound extracted from licorice, has chemopreventive and antitumor activities. The purpose of this study was to investigate the anticancer effect of ISL on human oral squamous cell carcinoma (OSCC).
METHODS: The anti-OSCC effects of ISL were evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test, flow cytometry, reverse transcription-polymerase chain reaction, Western blotting, promoter activity, terminal deoxynucleotidyl transferase dUTP nick-end labeling assay, malignant phenotype analysis, microRNA, and xenografting.
RESULTS: ISL induced OSCC cell cycle G2/M phase arrest, apoptosis, and DNA damage. However, the DNA repair-associated ataxia telangiectasia mutated (ATM) and phospho-ATM were downregulated, ATM mRNA remained unchanged, and the downstream signals were inhibited. ATM recovered when the caspase activity was blocked by Z-DVED-FMK. A low dose of ISL inhibited OSCC malignancy in vitro and reduced the tumor size in vivo.
CONCLUSION: ATM was cleaved by ISL-activated caspase, thus inhibiting DNA repair in OSCC cells. Therefore, ISL is a promising chemopreventive agent against oral cancer.
© 2015 Wiley Periodicals, Inc. Head Neck 38: E360-E371, 2016. © 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  DNA damage; apoptosis; ataxia telangiectasia mutated (ATM); isoliquiritigenin; oral squamous cell carcinoma (OSCC)

Mesh:

Substances:

Year:  2015        PMID: 25580586     DOI: 10.1002/hed.24001

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  21 in total

1.  WSB1 overcomes oncogene-induced senescence by targeting ATM for degradation.

Authors:  Jung Jin Kim; Seung Baek Lee; Sang-Yeop Yi; Sang-Ah Han; Sun-Hyun Kim; Jong-Min Lee; Seo-Yun Tong; Ping Yin; Bowen Gao; Jun Zhang; Zhenkun Lou
Journal:  Cell Res       Date:  2016-12-13       Impact factor: 25.617

2.  Low ATM protein expression in malignant tumor as well as cancer-associated stroma are independent prognostic factors in a retrospective study of early-stage hormone-negative breast cancer.

Authors:  Xiaolan Feng; Haocheng Li; Michelle Dean; Holly E Wilson; Elizabeth Kornaga; Emeka K Enwere; Patricia Tang; Alexander Paterson; Susan P Lees-Miller; Anthony M Magliocco; Gwyn Bebb
Journal:  Breast Cancer Res       Date:  2015-05-03       Impact factor: 6.466

Review 3.  Targeting microRNAs: a new action mechanism of natural compounds.

Authors:  Qian Lin; Leina Ma; Zhantao Liu; Zhihong Yang; Jin Wang; Jia Liu; Guohui Jiang
Journal:  Oncotarget       Date:  2017-02-28

4.  Isoliquiritigenin induces apoptosis and autophagy and inhibits endometrial cancer growth in mice.

Authors:  Chi-Hao Wu; Hsin-Yuan Chen; Chia-Woei Wang; Tzong-Ming Shieh; Tsui-Chin Huang; Li-Chun Lin; Kai-Lee Wang; Shih-Min Hsia
Journal:  Oncotarget       Date:  2016-11-08

5.  Synthetic Isoliquiritigenin Inhibits Human Tongue Squamous Carcinoma Cells through Its Antioxidant Mechanism.

Authors:  Cuilan Hou; Wenguang Li; Zengyou Li; Jing Gao; Zhenjie Chen; Xiqiong Zhao; Yaya Yang; Xiaoyu Zhang; Yong Song
Journal:  Oxid Med Cell Longev       Date:  2017-01-22       Impact factor: 6.543

6.  Isoliquiritigenin Induces Autophagy and Inhibits Ovarian Cancer Cell Growth.

Authors:  Hsin-Yuan Chen; Tsui-Chin Huang; Tzong-Ming Shieh; Chi-Hao Wu; Li-Chun Lin; Shih-Min Hsia
Journal:  Int J Mol Sci       Date:  2017-09-21       Impact factor: 5.923

7.  Ocoxin® oral solution slows down tumor growth in an experimental model of colorectal cancer metastasis to the liver in Balb/c mice.

Authors:  Joana Márquez; Jorge Mena; Iera Hernandez-Unzueta; Aitor Benedicto; Eduardo Sanz; Beatriz Arteta; Elvira Olaso
Journal:  Oncol Rep       Date:  2015-12-16       Impact factor: 3.906

8.  Targeting oral cancer stemness and chemoresistance by isoliquiritigenin-mediated GRP78 regulation.

Authors:  Fang-Wei Hu; Cheng-Chia Yu; Pei-Ling Hsieh; Yi-Wen Liao; Ming-Yi Lu; Pei-Ming Chu
Journal:  Oncotarget       Date:  2017-09-28

9.  Antitumoral effects of γCdcPLI, a PLA2 inhibitor from Crotalus durissus collilineatus via PI3K/Akt pathway on MDA-MB-231 breast cancer cell.

Authors:  Sarah N C Gimenes; Daiana S Lopes; Patrícia T Alves; Fernanda V P V Azevedo; Lara Vecchi; Luiz R Goulart; Thais C S Rodrigues; André L Q Santos; Vera L de C Brites; Thaise L Teixeira; Cláudio V da Silva; Matheus H Dias; Samuel C Teixeira; Renata S Rodrigues; Kelly A G Yoneyama; Ricardo A Oliveira; Veridiana de M Rodrigues
Journal:  Sci Rep       Date:  2017-08-01       Impact factor: 4.379

10.  Effects of isoliquiritigenin on ovarian cancer cells.

Authors:  Nan Li; Liang Yang; Xinna Deng; Yanan Sun
Journal:  Onco Targets Ther       Date:  2018-03-22       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.